If PCI is not possible or delayed, thrombolytic therapy should be considered as soon as possible.
Definite indications:
Probable indications:
Uncertain indications:
In the presence of a normal ECG, alternative diagnoses should be sought (e.g. aortic dissection, pericarditis, pulmonary embolus, peptic ulcer disease), and thrombolytic therapy not given. The 12 lead ECG must be repeated frequently if the clinical suspicion is high and pain continues.
If indicated, prescribe and administer tenecteplase in addition to all other drugs in Box 1 (provided there are no contraindications). Note, patients who are hypertensive should not receive thrombolysis until BP is controlled - see below for further advice.
Tenecteplase single weight adjusted IV bolus over 10 seconds | ||||
Weight | Weight (imperial) | Dose (units) | Dose (mg) | Volume |
<60kg | <9st 6lb | 6,000 units | 30mg | 6ml |
60–69.9kg | 9st 6lb–11st | 7,000 units | 35mg | 7ml |
70–79.9kg | 11st 1lb–12st 8lb | 8,000 units | 40mg | 8ml |
80–89.9kg | 12st 9lb–14st 2lb | 9,000 units | 45mg | 9ml |
>90kg | >14st 2lb | 10,000 units (max dose) | 50mg (max dose) | 10ml |
N.B. Tenecteplase must not be administered in a line containing glucose due to incompatibility. Alteplase or streptokinase can be used as an alternative if supplies of tenecteplase are unavailable - contact your clinical pharmacist or Medicines Information (see Appendix 6 for contact details) for further advice.
Patients who are hypertensive (systolic >200mmHg or diastolic >100 mmHg) should not receive thrombolysis for acute MI until their BP is controlled using the following measures:
Guideline reviewed | August 2023 |
Page updated | October 2023 |